HLA-DQB1*02–Restricted HPV-16 E7 Peptide–Specific CD4+ T-Cell Immune Responses Correlate with Regression of HPV-16–Associated High-Grade Squamous Intraepithelial Lesions
Open Access
- 15 April 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (8), 2479-2487
- https://doi.org/10.1158/1078-0432.ccr-06-2916
Abstract
Purpose: The fact that up to 30% of established high-grade squamous intraepithelial lesions (HSIL) of the cervix regress spontaneously presents the opportunity to identify clinically relevant human papillomavirus (HPV) viral epitopes associated with disease outcome. Two human HPV antigens, E6 and E7, are functionally required for initiation and maintenance of cervical cancer precursor lesions and invasive cervical cancer. The identification and characterization of endogenously processed HPV antigenic epitopes in closely characterized patient cohorts will provide insight into the reasons for success or failure of therapeutic approaches. Experimental Design: We characterized the HPV-16 E6/E7–specific T-cell epitopes using E6/E7 overlapping peptide pools with peripheral blood lymphocytes obtained from normal healthy donors. We then analyzed the difference in the HPV-16 T-cell immune responses in HPV-16+ HSIL patients with or without spontaneous regression of lesions using the statistical methods. Results: We have identified an HPV-16 E7–specific CD4+ T-cell epitope [amino acids (aa) 71-85] that was restricted by HLA-DQB1*0201. Analysis of peripheral blood lymphocytes obtained from 14 HLA-DQB1*02 patients with HPV-16+ HSILs showed that the HPV-16+ E7 peptide (aa 71-85)–specific CD4+ T-cell immune response was significantly higher in the group of patients with regression compared with the patients without regression (P value Conclusions: The HPV-16 E7 peptide–specific CD4+ T-cell immune response correlates with spontaneous regression of established HPV16+ HSILs. Thus, this E7 epitope may be useful for the characterization of HPV-specific immune responses in patients infected with HPV-16 or immunized with HPV vaccines.Keywords
All Related Versions
This publication has 25 references indexed in Scilit:
- HLA Class I Binding Promiscuity of the CD8 T-Cell Epitopes of Human Papillomavirus Type 16 E6 ProteinJournal of Virology, 2007
- How will HPV vaccines affect cervical cancer?Nature Reviews Cancer, 2006
- Spontaneous Regression of High-Grade Cervical Dysplasia: Effects of Human Papillomavirus Type and HLA PhenotypeClinical Cancer Research, 2005
- Disease-Stage Variance in Functional CD4+ T-Cell Responses Against Novel Pan-Human Leukocyte Antigen-D Region Presented Human Papillomavirus-16 E7 EpitopesClinical Cancer Research, 2004
- HPV DNA vaccinesFrontiers in Bioscience-Landmark, 2003
- Papillomaviruses and cancer: from basic studies to clinical applicationNature Reviews Cancer, 2002
- CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy.Journal of Clinical Investigation, 1997
- DNA VACCINESAnnual Review of Immunology, 1997
- Exposing the immunology of naked DNA vaccinesImmunity, 1995
- Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide PerspectiveJNCI Journal of the National Cancer Institute, 1995